These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 22351696

  • 1. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.
    Cheang MC, Voduc KD, Tu D, Jiang S, Leung S, Chia SK, Shepherd LE, Levine MN, Pritchard KI, Davies S, Stijleman IJ, Davis C, Ebbert MT, Parker JS, Ellis MJ, Bernard PS, Perou CM, Nielsen TO.
    Clin Cancer Res; 2012 Apr 15; 18(8):2402-12. PubMed ID: 22351696
    [Abstract] [Full Text] [Related]

  • 2. Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial.
    O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman D, Bramwell VH, Andrulis IL, Pritchard KI.
    Breast Cancer Res Treat; 2011 Jul 15; 128(2):401-9. PubMed ID: 21519837
    [Abstract] [Full Text] [Related]

  • 3. TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients.
    Hertel PB, Tu D, Ejlertsen B, Jensen MB, Balslev E, Jiang S, O'Malley FP, Pritchard KI, Shepherd LE, Bartels A, Brünner N, Nielsen TO.
    Breast Cancer Res Treat; 2012 Feb 15; 132(1):225-34. PubMed ID: 22160637
    [Abstract] [Full Text] [Related]

  • 4. Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial.
    Pritchard KI, Munro A, O'Malley FP, Tu D, Li X, Levine MN, Shepherd L, Chia S, Bartlett JM.
    Breast Cancer Res Treat; 2012 Jan 15; 131(2):541-51. PubMed ID: 22042366
    [Abstract] [Full Text] [Related]

  • 5. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
    O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, Andrulis IL, Pritchard KI.
    J Natl Cancer Inst; 2009 May 06; 101(9):644-50. PubMed ID: 19401546
    [Abstract] [Full Text] [Related]

  • 6. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
    Bartlett JM, Munro A, Cameron DA, Thomas J, Prescott R, Twelves CJ.
    J Clin Oncol; 2008 Nov 01; 26(31):5027-35. PubMed ID: 18768436
    [Abstract] [Full Text] [Related]

  • 7. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.
    Fountzilas G, Dafni U, Bobos M, Batistatou A, Kotoula V, Trihia H, Malamou-Mitsi V, Miliaras S, Chrisafi S, Papadopoulos S, Sotiropoulou M, Filippidis T, Gogas H, Koletsa T, Bafaloukos D, Televantou D, Kalogeras KT, Pectasides D, Skarlos DV, Koutras A, Dimopoulos MA.
    PLoS One; 2012 Nov 01; 7(6):e37946. PubMed ID: 22679488
    [Abstract] [Full Text] [Related]

  • 8. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients.
    Ejlertsen B, Jensen MB, Nielsen KV, Balslev E, Rasmussen BB, Willemoe GL, Hertel PB, Knoop AS, Mouridsen HT, Brünner N.
    J Clin Oncol; 2010 Feb 20; 28(6):984-90. PubMed ID: 20038724
    [Abstract] [Full Text] [Related]

  • 9. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
    Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N, National Cancer Institute of Canada Clinical Trials Group.
    J Clin Oncol; 2005 Aug 01; 23(22):5166-70. PubMed ID: 16051958
    [Abstract] [Full Text] [Related]

  • 10. HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
    Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, Levine MN, National Cancer Institute of Canada Clinical Trials Group.
    N Engl J Med; 2006 May 18; 354(20):2103-11. PubMed ID: 16707747
    [Abstract] [Full Text] [Related]

  • 11. Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.
    Liu S, Chapman JA, Burnell MJ, Levine MN, Pritchard KI, Whelan TJ, Rugo HS, Albain KS, Perez EA, Virk S, Barry G, Gao D, O'Brien P, Shepherd LE, Nielsen TO, Gelmon KA.
    Breast Cancer Res Treat; 2015 Jan 18; 149(2):439-48. PubMed ID: 25552364
    [Abstract] [Full Text] [Related]

  • 12. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
    Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdóttir K, Olsen KE, Mouridsen H, Ejlertsen B, Danish Breast Cancer Cooperative Group.
    J Clin Oncol; 2005 Oct 20; 23(30):7483-90. PubMed ID: 16234514
    [Abstract] [Full Text] [Related]

  • 13. The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.
    Jensen MB, Lænkholm AV, Nielsen TO, Eriksen JO, Wehn P, Hood T, Ram N, Buckingham W, Ferree S, Ejlertsen B.
    Breast Cancer Res; 2018 Jul 27; 20(1):79. PubMed ID: 30053900
    [Abstract] [Full Text] [Related]

  • 14. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
    Crump M, Tu D, Shepherd L, Levine M, Bramwell V, Pritchard K.
    J Clin Oncol; 2003 Aug 15; 21(16):3066-71. PubMed ID: 12915595
    [Abstract] [Full Text] [Related]

  • 15. Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the ABCSG Trial 5.
    Bago-Horvath Z, Rudas M, Singer CF, Greil R, Balic M, Lax SF, Kwasny W, Hulla W, Gnant M, Filipits M.
    Clin Cancer Res; 2020 Nov 01; 26(21):5682-5688. PubMed ID: 32546648
    [Abstract] [Full Text] [Related]

  • 16. Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur-uracil with CMF (N·SAS-BC 01 trial and CUBC trial).
    Ohno S, Saji S, Masuda N, Tsuda H, Akiyama F, Kurosumi M, Shimomura A, Sato N, Takao S, Ohsumi S, Tokuda Y, Inaji H, Watanabe T, Ohashi Y.
    Breast Cancer Res Treat; 2021 Feb 01; 186(1):135-147. PubMed ID: 33259001
    [Abstract] [Full Text] [Related]

  • 17. The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.
    Linardou H, Kalogeras KT, Kronenwett R, Kouvatseas G, Wirtz RM, Zagouri F, Gogas H, Christodoulou C, Koutras AK, Samantas E, Pectasides D, Bafaloukos D, Fountzilas G.
    Breast Cancer Res; 2012 Nov 12; 14(6):R145. PubMed ID: 23146280
    [Abstract] [Full Text] [Related]

  • 18. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15.
    Paik S, Bryant J, Tan-Chiu E, Yothers G, Park C, Wickerham DL, Wolmark N.
    J Natl Cancer Inst; 2000 Dec 20; 92(24):1991-8. PubMed ID: 11121461
    [Abstract] [Full Text] [Related]

  • 19. HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results.
    Colozza M, Sidoni A, Mosconi AM, Cavaliere A, Bisagni G, Gori S, De Angelis V, Frassoldati A, Cherubini R, Bian AR, Rodino C, Mazzocchi B, Mihailova Z, Bucciarelli E, Tonato M, Italian Oncology Group for Clincal Research.
    Clin Breast Cancer; 2005 Aug 20; 6(3):253-9. PubMed ID: 16137437
    [Abstract] [Full Text] [Related]

  • 20. Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer.
    Radice D, Redaelli A.
    Pharmacoeconomics; 2005 Aug 20; 23(1):69-75. PubMed ID: 15693729
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.